Sarepta Therapeutics, Inc. 10-Q

Item 5. Other Information . During the three months ended June 30, 2024 , no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K. Item 6. Exhibits. The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q. 74 EXHIBIT INDEX Incorporated by Reference to Filings Indicated Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Provided Herewith 3.1 Amended and Restated Certificate of Incorporation. 8-K12B 001-14895 3.1 6/6/13 3.2 Amendment to the Amended and Restated Certificate of Incorporation . 8-K 001-14895 3.1 6/30/15 3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Sarepta Therapeutics, Inc. 8-K 001-14895 3.1 6/8/20 3.4 Amended and Restated Bylaws. 8-K 001-14895 3.1 9/25/14 3.5 Amendment No. 1 to the Amended and Restated Bylaws. 8-K 001-14895 3.1 1/13/20 3.6 Second Amended and Restated Bylaws 8-K 001-14895 3.1 12/13/22 10.1 Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan 8-K 001-14895 10.1 6/7/2024 31.1 Certification of the Company’s Principal Executive Officer, Douglas S. Ingram, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of the Company’s Principal Financial and Accounting Officer, Ian M. Estepan, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1** Certification of the Company’s Principal Executive Officer, Douglas S. Ingram, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 32.2** Certification of the Company’s Principal Financial and Accounting Officer, Ian M. Estepan, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents X 104 Cover page formatted as Inline XBRL and contained in Exhibit 101 X † Indicates management contract or compensatory plan, contract or arrangement. * Certain identified information has been excluded from the exhibit. ** The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filings of Sarepta Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. 75 SIGNA TURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SAREPTA THERAPEUTICS, INC. (Registrant) Date: August 7, 2024 By: /s/ DOUGLAS S. INGRAM Douglas S. Ingram President and Chief Executive Officer (Principal Executive Officer) Date: August 7, 2024 By: /s/ IAN M. ESTEPAN Ian M. Estepan Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) 76